Apyx Medical Reports Preliminary Q4 Revenues Of ~$14.2M-$14.6M, Up 13%-16% Y/Y Versus Consensus Of $15.58M
Portfolio Pulse from Benzinga Newsdesk
Apyx Medical announced preliminary Q4 revenues of approximately $14.2M-$14.6M, reflecting a year-over-year increase of 13%-16%, which falls short of the consensus estimate of $15.58M. The Advanced Energy segment is expected to report revenue growth of 12%-16%, while OEM revenue is projected to grow by 14% compared to the same period last year.
January 08, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apyx Medical's Q4 revenue projection falls below consensus estimates, with a reported 13%-16% Y/Y growth compared to the expected $15.58M. Advanced Energy and OEM segments show growth, but the overall shortfall may concern investors.
The reported preliminary revenues for Apyx Medical are below the consensus estimates, which could lead to a negative short-term impact on the stock price as the market reacts to the earnings miss. The growth in specific segments is positive, but the overall miss may overshadow this in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100